Skip to content
drillr.ai
Sign up

06990.HK

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 437.80
+0.97%
Ask drillr

  • Oct 27, 2026, 10:00 UTC

    China’s National Medical Products Administration accepted Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s marketing application for an additional indication of sac-TMT in combination with pembrolizumab as first-line treatment for certain adults with advanced or metastatic non-squamous non-small cell lung cancer.

    Source:

  • Oct 27, 2026, 05:03 UTC

    Duality Biotherapeutics, Inc. announced clinical study results for elfetabart drozuntecan (DB-1311/BNT324, elfe-D) and DB-1310, including elfe-D combined with pumitamig and development progress in platinum-resistant ovarian cancer.

    Source:

  • Oct 27, 2026, 04:14 UTC

    Duality Biotherapeutics, Inc. reported positive phase III SAFFRON results for osimertinib plus savolitinib in 338 patients with EGFR-mutated, MET-overexpressing or amplified non-small cell lung cancer, including median progression-free survival of 7.6 months versus 5.4 months with chemotherapy and median overall survival of 17.8 months versus 12.9 months.

    Source:

  • Sep 21, 2026, 02:12 UTC

    Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

    Source:

  • Sep 8, 2026, 12:06 UTC

    Kelun-Biotech announced that its partner Windward Bio AG reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial for SKB378/WIN378, a TSLP-targeting monoclonal antibody for asthma, and the Phase 3 portion has been initiated.

    Source:

  • Aug 17, 2026, 11:11 UTC

    Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.

    Source:

  • Jul 30, 2026, 09:07 UTC

    Kelun-Biotech's new drug application for sac-TMT (TROP2 ADC) for a new indication in first-line treatment of recurrent or metastatic triple-negative breast cancer has been accepted for review by China's NMPA.

    Source:

  • Jul 28, 2026, 01:36 UTC

    China's National Medical Products Administration approved Hengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical to conduct Phase II/III clinical trials for HRS-1780 tablets for hypertension.

    Source:

  • Jul 27, 2026, 11:07 UTC

    Kelong Pharmaceutical's subsidiary Kelun-Biotech's SKB565 new drug clinical trial application was approved by China's National Medical Products Administration for the treatment of advanced solid tumors.

    Source:

  • Jul 21, 2026, 19:36 UTC

    Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.

    Source:

  • Jul 15, 2026, 10:02 UTC

    HBM7575/SKB575, a bispecific antibody for asthma, received IND approval from China's NMPA.

    Source: